4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment

Biogen’s BIIB080, a tau-targeting antisense oligonucleotide (ASO), is in Phase II trials with full enrollment announced in April 2025 and readouts expected in 2026.4

Alnylam’s mivelsiran, an siRNA therapy targeting amyloid-beta and tau, is in Phase I trials with plans for Phase II in late 2025.4

Trontinemab from Roche uses brain shuttle technology for faster amyloid clearance and is entering pivotal trials starting autumn 2025, with results expected by 2028.12

Remternetug from Eli Lilly is a third-generation anti-amyloid monoclonal antibody given via subcutaneous injection, clearing brain amyloid in 90-180 days, with Phase III trial readout in March 2026.19

Sources:

1. https://www.brightfocus.org/resource/the-next-generation-of-alzheimers-treatments/

2. https://www.alzheimersresearchuk.org/news/potential-alzheimers-treatment-trontinemab-hits-the-news-how-does-it-work-and-is-it-available/

4. https://www.biospace.com/drug-development/4-next-gen-candidates-that-could-form-the-future-of-alzheimers-treatment

9. https://www.clinicaltrialsarena.com/features/trials-to-watch-three-major-catalysts-in-alzheimers-disease/